Sirukumab Completed Phase 2 Trials for Critical Confirmed Coronavirus Disease (COVID)-19 / Coronavirus Disease 2019 (COVID‑19) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT04380961A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19